\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-tender\\ superficial\\ mass\\ at\\ the\\ left\\ superior\\ frontal\\ region\\ of\\ the\\ skull\\.\\ no\\ focal\\ neurological\\ deficits\\.\ \(0\)\
\-\ this\\ woman\\ was\\ known\\ to\\ have\\ multiple\\ myeloma\\ and\\ a\\ history\\ of\\ lytic\\ lesions\\.\\ \\ this\\ \\ evaluation\\ for\\ interval\\ change\\ led\\ to\\ treatment\\ with\\ focused\\ radiotherapy\\.\ \(0\)\
\-\ plain\\ radiograph\\ \\(skull\\)\\:\\ multiple\\ \\‚\\Ä\\úpunched\\-out\\‚\\Ä\\ù\\ lytic\\ lesions\\ are\\ seen\\ throughout\\ the\\ calvarium\\.\\ \\ \ \(0\)\
\-\ a\\ large\\ lytic\\ lesion\\ at\\ the\\ vertex\\ disrupts\\ both\\ the\\ inner\\ and\\ outer\\ table\\.\ \(0\)\
\-\ t1\\ sag\\:\\ large\\ expansile\\ mass\\ lesion\\ which\\ is\\ hypointense\\ to\\ bone\\ marrow\\ extending\\ intracranially\\ from\\ the\\ frontal\\ clavarium\\.\ \(0\)\
\-\ t1\\ cor\\:\\ \\ large\\ expansile\\ mass\\ lesion\\ which\\ is\\ hypointense\\ to\\ bone\\ marrow\\ extending\\ intracranially\\ from\\ the\\ frontal\\ clavarium\\.\ \(0\)\
\-\ t1\\ ax\\ \\+c\\:\\ enhancing\\ expansile\\ mass\\ lesion\\ extending\\ intracranially\\ and\\ superficially\\ from\\ the\\ calvarium\\.\ \(0\)\
\-\ t1\\ cor\\ \\+c\\:\\ enhancing\\ expansile\\ mass\\ lesion\\ extending\\ intracranially\\ and\\ superficially\\ from\\ the\\ calvarium\\.\ \(0\)\
\-\ t2\\ ax\\:\\ expansile\\ mass\\ which\\ is\\ isointense\\ to\\ bone\\ marrow\\ extending\\ both\\ intracranially\\ and\\ superficially\\ from\\ the\\ calvarium\\.\ \(0\)\
\-\ multiple\\ myeloma\ \(25\)\
\-\ \\‚\\Ä\\¢\\ surgical\\ defect\ \(0\)\
\-\ \\‚\\Ä\\¢\\ lytic\\ metastasis\ \(0\)\
\-\ \\‚\\Ä\\¢\\ hemangioma\ \(0\)\
\-\ \\‚\\Ä\\¢\\ brown\\ tumor\ \(0\)\
\-\ \\‚\\Ä\\¢\\ hemangiopericytoma\ \(1\)\
\-\ \\‚\\Ä\\¢\\ meningioma\\ \\(multiple\\ or\\ meningiomatosis\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\ multiple\\ myeloma\ \(0\)\
\-\ 61\\ y\\.o\\.\\ woman\\ with\\ a\\ \\"lump\\"\\ on\\ left\\ side\\ of\\ head\\.\ \(1\)\
\-\ multiple\\ myeloma\\ is\\ characterized\\ by\\ the\\ neoplastic\\ proliferation\\ of\\ a\\ single\\ line\\ of\\ plasma\\ cells\\ producing\\ a\\ monoclonal\\ immunoglobulin\\.\\ this\\ proliferation\\ replaces\\ normal\\ bone\\ marrow\\ and\\ often\\ results\\ in\\ extensive\\ skeletal\\ destruction\\ with\\ osteolytic\\ lesions\\,\\ osteopenia\\,\\ and\\/or\\ pathologic\\ fractures\\.\\ \\ \ \(0\)\
\-\ the\\ etiology\\ of\\ multiple\\ myeloma\\ is\\ unknown\\.\\ \\ it\\ is\\ more\\ common\\ in\\ the\\ elderly\\ and\\ there\\ is\\ a\\ slight\\ increased\\ risk\\ among\\ children\\ and\\ siblings\\ of\\ multiple\\ myeloma\\ patients\\.\\ \\ there\\ is\\ also\\ an\\ increased\\ incidence\\ amongst\\ petroleum\\,\\ leather\\,\\ and\\ cosmetology\\ workers\\.\\ \\ additionally\\,\\ exposure\\ to\\ radiation\\ \\(greater\\ than\\ 50\\ rad\\)\\,\\ hebricides\\,\\ insecticides\\,\\ heavy\\ metals\\,\\ plastics\\,\\ and\\ asbestos\\ also\\ increases\\ risk\\.\\ \\ \ \(0\)\
\-\ \\‚\\Ä\\úpunched\\-out\\‚\\Ä\\ù\\ lytic\\ lesions\\ are\\ a\\ common\\ finding\\ on\\ plain\\ film\\.\\ \\ an\\ osteolytic\\ skull\\ lesion\\ is\\ the\\ best\\ diagnostic\\ clue\\ on\\ imaging\\.\\ \\ the\\ appearance\\ can\\ vary\\ on\\ t1\\-weighted\\ mri\\,\\ ranging\\ from\\ focal\\ hyperintensity\\ in\\ 53\\%\\ of\\ cases\\ to\\ a\\ focal\\ hypointensity\\ in\\ 25\\%\\ of\\ cases\\.\\ \\ marked\\ lesional\\ enhancement\\ is\\ seen\\ following\\ gadolinium\\ administration\\.\\ \\ on\\ t2\\ weighted\\ imaging\\,\\ an\\ iso\\-\\ to\\ hyperintense\\ lesion\\ can\\ be\\ seen\\.\\ \\ intracranial\\ myeloma\\,\\ as\\ in\\ this\\ patient\\,\\ is\\ a\\ rare\\ finding\\.\ \(0\)\
\-\ references\\:\\ \ \(0\)\
\-\ angtuaco\\ ej\\,\\ et\\ al\\.\\ \\ multiple\\ myeloma\\:\\ clinical\\ review\\ and\\ diagnostic\\ imaging\\.\\ \\ radiology\\.\\ \\ 2004\\;\\ 231\\(1\\)\\:11\\-23\\.\ \(0\)\
\-\ brant\\ we\\,\\ helms\\ ca\\.\\ \\ fundamentals\\ of\\ diagnostic\\ radiology\\.\\ lippincott\\,\\ williams\\ \\&\\ wilkins\\.\\ philadelphia\\.\\ 2007\ \(0\)\
\-\ osborn\\ ag\\.\\ \\ diagnostic\\ neuroradiology\\.\\ mosby\\.\\ st\\ louis\\.\\ 1994\\.\\ \ \(0\)\
\-\ smith\\,\\ a\\,\\ wisloff\\,\\ f\\,\\ samson\\,\\ d\\.\\ guidelines\\ on\\ the\\ diagnosis\\ and\\ management\\ of\\ multiple\\ myeloma\\ 2005\\.\\ british\\ journal\\ of\\ haematology\\.\\ \\ 2006\\;\\ 132\\:410\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ myeloma\\:\\ 0\\.3809903160526162\ \(0\)\
\-\ intracranially\\:\\ 0\\.2722098355253818\ \(0\)\
\-\ multiple\\:\\ 0\\.19938470311927653\ \(0\)\
\-\ calvarium\\:\\ 0\\.1922187066243544\ \(0\)\
\-\ expansile\\:\\ 0\\.18442973312205865\ \(0\)\
\-\ superficially\\:\\ 0\\.17592700580694165\ \(0\)\
\-\ lytic\\:\\ 0\\.17168560188498774\ \(0\)\
\-\ extending\\:\\ 0\\.13819195468952405\ \(0\)\
\-\ lesion\\:\\ 0\\.13680156640480137\ \(0\)\
\-\ marrow\\:\\ 0\\.13550369280679125\ \(0\)\
\-\ clavarium\\:\\ 0\\.13038043690648046\ \(0\)\
\-\ the\\:\\ 0\\.13014173839894463\ \(0\)\
\-\ t1\\:\\ 0\\.12699202789933742\ \(0\)\
\-\ diagnostic\\:\\ 0\\.1242733106706199\ \(0\)\
\-\ is\\:\\ 0\\.12279793202053464\ \(0\)\
\-\ ax\\:\\ 0\\.11467890314486005\ \(0\)\
\-\ and\\:\\ 0\\.10950346955411928\ \(0\)\
\-\ cor\\:\\ 0\\.10477233831794695\ \(0\)\
\-\ skull\\:\\ 0\\.09922214337487531\ \(0\)\
\-\ from\\:\\ 0\\.09713796057101444\ \(0\)\
\-\ of\\:\\ 0\\.0957275838100332\ \(0\)\
\-\ osteolytic\\:\\ 0\\.09547404196715698\ \(0\)\
\-\ lesions\\:\\ 0\\.09364449115697235\ \(0\)\
\-\ mass\\:\\ 0\\.0934241404590085\ \(0\)\
\-\ bone\\:\\ 0\\.08896803736541906\ \(0\)\
\-\ proliferation\\:\\ 0\\.08756497605722181\ \(0\)\
\-\ to\\:\\ 0\\.08152699437312291\ \(0\)\
\-\ frontal\\:\\ 0\\.07871005058032664\ \(0\)\
\-\ on\\:\\ 0\\.07386823546507085\ \(0\)\
\-\ focal\\:\\ 0\\.07314921942901279\ \(0\)\
\-\ hypointense\\:\\ 0\\.07174483454478701\ \(0\)\
\-\ radiology\\:\\ 0\\.0652957364190914\ \(0\)\
\-\ disrupts\\:\\ 0\\.06519021845324023\ \(0\)\
\-\ meningiomatosis\\:\\ 0\\.06519021845324023\ \(0\)\
\-\ leather\\:\\ 0\\.06519021845324023\ \(0\)\
\-\ cosmetology\\:\\ 0\\.06519021845324023\ \(0\)\
\-\ hebricides\\:\\ 0\\.06519021845324023\ \(0\)\
\-\ insecticides\\:\\ 0\\.06519021845324023\ \(0\)\
\-\ angtuaco\\:\\ 0\\.06519021845324023\ \(0\)\
\-\ wisloff\\:\\ 0\\.06519021845324023\ \(0\)\
\-\ samson\\:\\ 0\\.06519021845324023\ \(0\)\
\-\ imaging\\:\\ 0\\.06426829687534387\ \(0\)\
\-\ petroleum\\:\\ 0\\.06229273398588658\ \(0\)\
\-\ metals\\:\\ 0\\.06229273398588658\ \(0\)\
\-\ 231\\:\\ 0\\.06229273398588658\ \(0\)\
\-\ haematology\\:\\ 0\\.06229273398588658\ \(0\)\
\-\ large\\:\\ 0\\.061274088196174796\ \(0\)\
\-\ weighted\\:\\ 0\\.060812894928286176\ \(0\)\
\-\ workers\\:\\ 0\\.05864233526898055\ \(0\)\
\-\ plastics\\:\\ 0\\.05864233526898055\ \(0\)\
\-\ british\\:\\ 0\\.05864233526898055\ \(0\)\
\-\ risk\\:\\ 0\\.0582530092822877\ \(0\)\
\-\ seen\\:\\ 0\\.05757382563335745\ \(0\)\
\-\ amongst\\:\\ 0\\.05733945157243003\ \(0\)\
\-\ ej\\:\\ 0\\.05733945157243003\ \(0\)\
\-\ this\\:\\ 0\\.05602872712412896\ \(0\)\
\-\ which\\:\\ 0\\.05560714016193898\ \(0\)\
\-\ replaces\\:\\ 0\\.055283653626327145\ \(0\)\
\-\ lesional\\:\\ 0\\.055283653626327145\ \(0\)\
\-\ cases\\:\\ 0\\.05483585790149791\ \(0\)\
\-\ plain\\:\\ 0\\.05378962372808376\ \(0\)\
\-\ monoclonal\\:\\ 0\\.05368905285552401\ \(0\)\
\-\ siblings\\:\\ 0\\.05368905285552401\ \(0\)\
\-\ clue\\:\\ 0\\.05368905285552401\ \(0\)\
\-\ osborn\\:\\ 0\\.05368905285552401\ \(0\)\
\-\ finding\\:\\ 0\\.05358926317644127\ \(0\)\
\-\ immunoglobulin\\:\\ 0\\.05238616915897348\ \(0\)\
\-\ sag\\:\\ 0\\.05181417788877241\ \(0\)\
\-\ neuroradiology\\:\\ 0\\.05128459668948163\ \(0\)\
\-\ enhancing\\:\\ 0\\.051072198329964416\ \(0\)\
\-\ ag\\:\\ 0\\.05079156838817034\ \(0\)\
\-\ in\\:\\ 0\\.05070357417229163\ \(0\)\
\-\ brant\\:\\ 0\\.049897143059474354\ \(0\)\
\-\ guidelines\\:\\ 0\\.049488684691619815\ \(0\)\
\-\ helms\\:\\ 0\\.04910231622071847\ \(0\)\
\-\ vertex\\:\\ 0\\.04873577044206746\ \(0\)\
\-\ ranging\\:\\ 0\\.04873577044206746\ \(0\)\
\-\ focused\\:\\ 0\\.048387112222127965\ \(0\)\
\-\ louis\\:\\ 0\\.0480546766560886\ \(0\)\
\-\ fundamentals\\:\\ 0\\.04773702098357849\ \(0\)\
\-\ plasma\\:\\ 0\\.04743288674551693\ \(0\)\
\-\ asbestos\\:\\ 0\\.04714116967126431\ \(0\)\
\-\ t2\\:\\ 0\\.04690509886529119\ \(0\)\
\-\ st\\:\\ 0\\.04686089547531586\ \(0\)\
\-\ an\\:\\ 0\\.04676384090890625\ \(0\)\
\-\ heavy\\:\\ 0\\.04633131427602509\ \(0\)\
\-\ common\\:\\ 0\\.046235507268147236\ \(0\)\
\-\ vary\\:\\ 0\\.04583828597471379\ \(0\)\
\-\ hypointensity\\:\\ 0\\.045603967409646166\ \(0\)\
\-\ both\\:\\ 0\\.04546381366334893\ \(0\)\
\-\ brown\\:\\ 0\\.044943860646017804\ \(0\)\
\-\ lippincott\\:\\ 0\\.04453540227816327\ \(0\)\
\-\ wilkins\\:\\ 0\\.04433960712700489\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.04414903380726193\ \(0\)\
\-\ increased\\:\\ 0\\.0440862682763462\ \(0\)\
\-\ led\\:\\ 0\\.0439634110079622\ \(0\)\
\-\ hemangiopericytoma\\:\\ 0\\.04326567908647178\ \(0\)\
\-\ among\\:\\ 0\\.043101394242632055\ \(0\)\
\-\ elderly\\:\\ 0\\.04294080150736012\ \(0\)\
\-\ increases\\:\\ 0\\.042783738570121944\ \(0\)\
\-\ williams\\:\\ 0\\.042783738570121944\ \(0\)\
\-\ can\\:\\ 0\\.04278312000717434\ \(0\)\
\-\ lump\\:\\ 0\\.042630053593700146\ \(0\)\
\-\ woman\\:\\ 0\\.04245985884830383\ \(0\)\
\-\ osteopenia\\:\\ 0\\.04233225733917958\ \(0\)\
\-\ mosby\\:\\ 0\\.04233225733917958\ \(0\)\
\-\ table\\:\\ 0\\.04190761306185932\ \(0\)\
\-\ producing\\:\\ 0\\.04190761306185932\ \(0\)\
\-\ 61\\:\\ 0\\.04137803186256854\ \(0\)\
\-\ journal\\:\\ 0\\.04137803186256854\ \(0\)\
\-\ philadelphia\\:\\ 0\\.04125154933990827\ \(0\)\
\-\ hyperintensity\\:\\ 0\\.04065068499618962\ \(0\)\
\-\ 2006\\:\\ 0\\.04065068499618962\ \(0\)\
\-\ 2007\\:\\ 0\\.040313012291056174\ \(0\)\
\-\ smith\\:\\ 0\\.040313012291056174\ \(0\)\
\-\ inner\\:\\ 0\\.039886254102768276\ \(0\)\
\-\ superficial\\:\\ 0\\.039386324713548346\ \(0\)\
\-\ outer\\:\\ 0\\.039195751393805385\ \(0\)\
\-\ we\\:\\ 0\\.039195751393805385\ \(0\)\
\-\ rad\\:\\ 0\\.03891909454846519\ \(0\)\
\-\ exposure\\:\\ 0\\.038740433343455935\ \(0\)\
\-\ 2004\\:\\ 0\\.038395977461758116\ \(0\)\
\-\ also\\:\\ 0\\.03834826295609807\ \(0\)\
\-\ 53\\:\\ 0\\.038148111829175504\ \(0\)\
\-\ neoplastic\\:\\ 0\\.0376767711802436\ \(0\)\
\-\ characterized\\:\\ 0\\.037452268655145275\ \(0\)\
\-\ destruction\\:\\ 0\\.037163499024107885\ \(0\)\
\-\ skeletal\\:\\ 0\\.03695433064840277\ \(0\)\
\-\ interval\\:\\ 0\\.03688594662441173\ \(0\)\
\-\ isointense\\:\\ 0\\.03688594662441173\ \(0\)\
\-\ slight\\:\\ 0\\.03569740258273307\ \(0\)\
\-\ incidence\\:\\ 0\\.035090034626549915\ \(0\)\
\-\ deficits\\:\\ 0\\.03503729581910471\ \(0\)\
\-\ ca\\:\\ 0\\.03477928671288994\ \(0\)\
\-\ hemangioma\\:\\ 0\\.03428963796991735\ \(0\)\
\-\ gadolinium\\:\\ 0\\.03396581213500865\ \(0\)\
\-\ additionally\\:\\ 0\\.03356992824862145\ \(0\)\
\-\ review\\:\\ 0\\.03356992824862145\ \(0\)\
\-\ neurological\\:\\ 0\\.033484854910848044\ \(0\)\
\-\ pathologic\\:\\ 0\\.03340078245909805\ \(0\)\
\-\ children\\:\\ 0\\.03340078245909805\ \(0\)\
\-\ etiology\\:\\ 0\\.03283844152928866\ \(0\)\
\-\ best\\:\\ 0\\.032799918115379405\ \(0\)\
\-\ intracranial\\:\\ 0\\.032799918115379405\ \(0\)\
\-\ references\\:\\ 0\\.032498986241688725\ \(0\)\
\-\ administration\\:\\ 0\\.03246224541024596\ \(0\)\
\-\ there\\:\\ 0\\.032439592928893056\ \(0\)\
\-\ hyperintense\\:\\ 0\\.03242569251226648\ \(0\)\
\-\ al\\:\\ 0\\.03238932563492904\ \(0\)\
\-\ et\\:\\ 0\\.03193266421095519\ \(0\)\
\-\ line\\:\\ 0\\.031764513488755544\ \(0\)\
\-\ results\\:\\ 0\\.031764513488755544\ \(0\)\
\-\ cells\\:\\ 0\\.03140794594208277\ \(0\)\
\-\ extensive\\:\\ 0\\.03140794594208277\ \(0\)\
\-\ single\\:\\ 0\\.03134498451299517\ \(0\)\
\-\ are\\:\\ 0\\.030936029609593067\ \(0\)\
\-\ change\\:\\ 0\\.03088966646264573\ \(0\)\
\-\ unknown\\:\\ 0\\.03088966646264573\ \(0\)\
\-\ marked\\:\\ 0\\.03083109174146334\ \(0\)\
\-\ at\\:\\ 0\\.030794019834233737\ \(0\)\
\-\ rare\\:\\ 0\\.030772993242794103\ \(0\)\
\-\ meningioma\\:\\ 0\\.0305452105809479\ \(0\)\
\-\ film\\:\\ 0\\.030461629792205024\ \(0\)\
\-\ fractures\\:\\ 0\\.03013675221309337\ \(0\)\
\-\ management\\:\\ 0\\.030110334157223962\ \(0\)\
\-\ greater\\:\\ 0\\.030031660966561523\ \(0\)\
\-\ throughout\\:\\ 0\\.029979689275855183\ \(0\)\
\-\ defect\\:\\ 0\\.02990243364802574\ \(0\)\
\-\ metastasis\\:\\ 0\\.029876866264852302\ \(0\)\
\-\ 25\\:\\ 0\\.028878116806363336\ \(0\)\
\-\ 50\\:\\ 0\\.028468425612494522\ \(0\)\
\-\ or\\:\\ 0\\.02836201248776493\ \(0\)\
\-\ side\\:\\ 0\\.02816079952194521\ \(0\)\
\-\ left\\:\\ 0\\.027810854400252126\ \(0\)\
\-\ radiation\\:\\ 0\\.027013492010110288\ \(0\)\
\-\ often\\:\\ 0\\.026598388336985357\ \(0\)\
\-\ radiograph\\:\\ 0\\.02655015816983006\ \(0\)\
\-\ superior\\:\\ 0\\.026502251335834365\ \(0\)\
\-\ known\\:\\ 0\\.026391702099538623\ \(0\)\
\-\ clinical\\:\\ 0\\.025834191231402816\ \(0\)\
\-\ evaluation\\:\\ 0\\.02486006275782308\ \(0\)\
\-\ appearance\\:\\ 0\\.02457492563145627\ \(0\)\
\-\ following\\:\\ 0\\.02445441559219757\ \(0\)\
\-\ region\\:\\ 0\\.02438307314300426\ \(0\)\
\-\ head\\:\\ 0\\.024312435902543655\ \(0\)\
\-\ with\\:\\ 0\\.023946195254637266\ \(0\)\
\-\ enhancement\\:\\ 0\\.02346294372680404\ \(0\)\
\-\ than\\:\\ 0\\.023107849161283618\ \(0\)\
\-\ patients\\:\\ 0\\.022931876702375564\ \(0\)\
\-\ more\\:\\ 0\\.022383695786477715\ \(0\)\
\-\ tumor\\:\\ 0\\.021321841636211796\ \(0\)\
\-\ diagnosis\\:\\ 0\\.021131674055346106\ \(0\)\
\-\ mri\\:\\ 0\\.020924526914550243\ \(0\)\
\-\ it\\:\\ 0\\.02086642841588101\ \(0\)\
\-\ have\\:\\ 0\\.02036376278880153\ \(0\)\
\-\ surgical\\:\\ 0\\.019812545009898014\ \(0\)\
\-\ treatment\\:\\ 0\\.019417969261220722\ \(0\)\
\-\ by\\:\\ 0\\.017310681095623705\ \(0\)\
\-\ normal\\:\\ 0\\.016643593342916964\ \(0\)\
\-\ be\\:\\ 0\\.016536251101363513\ \(0\)\
\-\ as\\:\\ 0\\.01637627220350836\ \(0\)\
\-\ history\\:\\ 0\\.015574138122876646\ \(0\)\
\-\ was\\:\\ 0\\.014206593971148032\ \(0\)\
\-\ patient\\:\\ 0\\.01325842343504221\ \(0\)\
\-\ no\\:\\ 0\\.013255929602884983\ \(0\)\
\-\ for\\:\\ 0\\.012355200227766181\ \(0\)\
